Even though some drugs tailored to the breast cancer cell types, such as hormonal agents for ER-positive cells and HER2 targeted agents for HER2 positive cells, have achieved clinical effects to some extent, chemotherapeutic options for triple-negative phenotype breast cancers are very limited. Here, ESR1 is linked to breast carcinoma.